ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,136.99
0.42%
Dow Jones
43,297.03
0.91%
Gold vs US Dollar
2,616.45
0.00%
Brent Oil
73.285
0.00%
Bitcoin
98,550.71
-0.13%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. uniQure NV (QURE) Share Price

QURE uniQure NV

17.35
-0.08 (-0.46%)
24 Dec 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 uniQure NV NASDAQ:QURE NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.08 -0.46 17.35 17.30 17.48 18.12 16.81 17.88 429,042 22:00:00   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations 21.9M -308.48M -6.3286 -2.74 849.59M
 Type  Size  Price  Time  Units 
 20 100 17.35 21:38:10 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore QURE News
10/12/202421:54EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
10/12/202421:33EDGAR2Form 144 - Report of proposed sale of securities
10/12/202412:22EDGAR2Form 8-K - Current report
10/12/202412:05GLOBEuniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
21/11/202414:00EDGAR2Form 8-K - Current report
21/11/202412:05GLOBEuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
14/11/202417:01EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Period
Draw mode
Data Downloads for QURE

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest uniQure NV Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads